TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04489108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Tranexamic Acid 1g iv bolus as loading dose followed by 3g Tranexamic Acid infused over next 24 hours

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: isotonic solution (saline)
Study: NCT01572740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Liraglutide administered subcutaneously (s.c., under the skin) for 36 weeks combined with insulin therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Liraglutide placebo administered subcutaneously (s.c., under the skin) for 36 weeks combined with insulin therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin
Description: All subjects will continue their pre-trial insulin therapy (basal, premixed or basal-bolus regimen) during the trial. Insulin dose is fixed for the first 16 weeks and for the subsequent 20 weeks, insulin dose is individually adjusted.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: insulin
Description: All subjects will continue their pre-trial insulin therapy (basal, premixed or basal-bolus regimen) during the trial. Insulin dose is fixed for the first 16 weeks and for the subsequent 20 weeks, insulin dose is individually adjusted.
Study: NCT00515788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DepoCyt
Description: Starting dose of 50 mg Intrathecal on Day 1 every 14 days for a total of 12 weeks (6 treatments). After the first 12 weeks, 50 mg Intrathecal on Day 1 every 28 days for 40 weeks (10 treatments).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 100 mg/m\^2 (capsules) by mouth daily for 7 consecutive days every 14 days.
Study: NCT02864277

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Intervention Conventional Strategy
Description: The Conventional Strategy Group description encompasses over 4 pages of concise directions on how to take care of the participant. This cannot be reduced to less than 1000 characters.~Preoperative Management Interoperative Management Postoperative Management Post discharge

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS
Description: The ERAS Group description encompasses over 3 pages of concise directions on how to take care of the participant. This cannot be reduced to less than 1000 characters.~Preoperative Management Interoperative Management Postoperative Management Post discharge
Study: NCT01315470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neupogen administration for women with recurrent IVF failure
Description: neupogen 300 mcg - twice
Study: NCT02727153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultra E.R.A.S.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classic E.R.A.S.
Study: NCT01893476

Intervention type: OTHER
Group type: OTHER
Intervention: Implementation educational programme
Description: Implementation educational programme will include: brief anti-smoking counseling, mMRC scale, checklist, training patient on correct use of inhaling. Participating physicians will receive training in brief anti-smoking counselling and will be asked to record information about. Additional form containing the mMRC dyspnoea scale will be inserted into patients' medical records. We will elaborate a checklist for practitioners with information about what should be done while consulting a patient with COPD. Investigators will provide practices with training inhaler and train staff. Practitioners will be asked to teach patients in correct use of each device. Practitioners will be asked to put this information to the patient's medical records.
Study: NCT03157596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Health Educational Program for Caregivers of Children with developmental disabilities
Description: Oral Health Education Program for Caregivers of Children with developmental disabilities included information about health issues and obstacles encountered in children with DD \& methods of prevention and management. It also emphasized on proper oral hygiene measures for this group. (University of Washington 2010)
Study: NCT02740790

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV vaccine
Description: Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV vaccine
Description: Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV vaccine
Description: Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
Study: NCT02374619

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron supplement Resoferon Ferrous Sulfate
Description: Oral supplementation with one tablet of iron supplement \[Resoferon Ferrous Sulfate 125 (37) mg\]

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03627078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor interference therapy

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Relaxation exercises
Description: In a top-down sequence, beginning with the upper body and proceeding to the lower parts. patients contract and relax a specific muscle group following the instructions given by the audio track. We use a shorter version that excludes the legs because of the time.
Study: NCT01889732

Intervention type: DEVICE
Intervention: ROTEM
Study: NCT03513471

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: A single 1mg/kg subcutaneous injection (up to 100mg) of anakinra will be administered at the onset of the EPR, directly after the allergen challenge, to model anakinra use in an emergency care setting.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: A single 1mg/kg subcutaneous injection (up to 100mg) of anakinra will be administered at the onset of the EPR, directly after the allergen challenge, to model anakinra use in an emergency care setting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anakinra Matching Placebo
Description: A single dose of matching placebo will be administered at the onset of the EPR, directly after the allergen challenge, to model anakinra use in an emergency care setting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anakinra Matching Placebo
Description: A single dose of matching placebo will be administered at the onset of the EPR, directly after the allergen challenge, to model anakinra use in an emergency care setting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermatophagoides Farinae
Description: Standardized house dust mite Dermatophagoides farinae (D. farinae) allergen extract at 30,000 allergen units (AU)/mL for inhalation (provided by Greer Laboratories, Lenoir, NC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermatophagoides Farinae
Description: Standardized house dust mite Dermatophagoides farinae (D. farinae) allergen extract at 30,000 allergen units (AU)/mL for inhalation (provided by Greer Laboratories, Lenoir, NC).
Study: NCT04537013

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: Debridement of cartilage followed by placement of small holes in the effected area to fill the debrided area with marrow and cells.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microfracture plus placement of Chondro-Gide® ACC
Description: Debridement of cartilage followed by placement of small holes in the effected area to fill the debrided area with marrow and cells, followed by affixing Chondro-Gide® with fibrin glue.
Study: NCT00568893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drotrecogin alfa (activated)
Study: NCT04705532

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Multi-channel tDCS will be applied over the executive network for 20 minutes at 4mA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Multi-channel tDCS will be applied over the executive network for 20 minutes at 4mA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Description: Sham tDCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tDCS condition and the electrodes placement as well.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Description: Sham tDCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tDCS condition and the electrodes placement as well.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Subjects will listen to their preferred music for 20 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Subjects will listen to their preferred music for 20 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White noise
Description: Subjects will listen to a white noise for 20 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White noise
Description: Subjects will listen to a white noise for 20 minutes
Study: NCT03488563

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B244
Description: B244 Suspension

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B244
Description: B244 Suspension

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Suspension
Study: NCT00888498

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Passive Positioning
Description: With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface, which is similar to the positioning used for the active comparator groups. The treating investigator will maintain passive positioning of the ankle for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Velocity, Low-Amplitude Stretch
Description: With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slow, Mobilization Stretch
Description: With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating therapist's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
Study: NCT03592849

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UC-MSCs therapy
Description: After history taking, physical examination, ultrasound examination and hysteroscopy examination，infertile women diagnosed with thin endometrium or endometrial scarring will be included in the clinical trial. A collagen scaffold loaded with UC-MSCs will be transplanted into the uterine cavity during hysteroscopy, and participants will receive hormone replacement therapy before and after the treatment. Postoperative observations including ultrasound examination once a month for 3 times and hysteroscopy in the third month after first UC-MSCs therapy. Those whose endometrium is suitable for pregnancy will be recommended attempting conception actively. The next round of cell therapy will be conducted 3 cycles after the first month if the endometrial growth is unsatisfactory.
Study: NCT01204918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Riluzole 100mg PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Riluzole 100mg PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo
Study: NCT01088711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Once-weekly 50 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Once-weekly 50 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-weekly placebo capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-weekly placebo capsule
Study: NCT04539548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza Ophthalmic Insert
Description: 0.4mg insert for intracanalicular use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone acetate ophthalmic suspension USP 1%
Description: 1 drop at end of surgery, followed by:~1 drop 4 x QID for one week.~1 drop 3 x QID for one week.~1 drop BID for one week.~1 drop QD for one week
Study: NCT02025933

Intervention type: OTHER
Intervention: Salmon Group
Description: The children are advised to eat at least 75g of salmon per serving, but no more than 150g

Intervention type: OTHER
Intervention: Cod Group
Description: The children are advised to eat at least 75g of cod per serving, but no more than 150g

Intervention type: OTHER
Intervention: Meat Group
Description: The children are advised to eat at least 75g of meat per serving, but no more than 150g
Study: NCT06365190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: During treatment, the patient underwent cTBS targeting the left SMA for 14 consecutive days. Each treatment day comprised three rounds of cTBS, with a 15-minute interval between each. A single cTBS session involved trains of three pulses at 50 Hz, repeated every 200 ms (5 Hz), until reaching a total of 600 pulses, lasting 40s. Stimulation intensity remained at 80% of resting motor threshold. In total, patients received 25,200 pulses throughout the treatment period.

Intervention type: DRUG
Group type: OTHER
Intervention: Pharmacotherapy（antiparkinsonian drugs）
Description: Anti-Parkinson's disease drugs include compound levodopa, dopamine receptor agonists, monoamine oxidase type B inhibitors, catechol-O-methyl transferase inhibitors, etc. Take dopaminergic agents regularly, with follow-up every 8 weeks including medication guidance and symptom assessment
Study: NCT03188523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8504
Description: After at least an 8-hour fast, a single oral dose of MK-8504 will be administered in capsule form.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8504
Description: After at least an 8-hour fast, a single oral dose of MK-8504 will be administered in capsule form.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8504
Description: After at least an 8-hour fast, a single oral dose of MK-8504 will be administered in capsule form.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8504
Description: After at least an 8-hour fast, a single oral dose of MK-8504 will be administered in capsule form.
Study: NCT04640740

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hip arthroplasty
Description: two different approaches of total hip arthroplasty

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hip arthroplasty
Description: two different approaches of total hip arthroplasty
Study: NCT03122470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI guided biopsy
Description: The MRI guided biopsy will preferentially be performed using a 3 tesla (3T) Siemens Verio, or 3T Siemens Skyra machine. The multiparametric MRI exam will consist of T1-, T2- and diffusion weighted imaging with or without post-contrast perfusion studies. magnetic resonance fingerprinting (MRF) will be performed before contrast injection. The MRI will be interpreted by two specified radiologists from the research team.
Study: NCT03961750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OTAGO
Description: 12 Week exercise class programme
Study: NCT01887288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 650 mg/m\^2 PO b.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: 0.25 mg once daily
Study: NCT04403165

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nocturnal polysomnography (NPSG)
Description: Nocturnal polysomnography (NPSG) to measure REM sleep and sleep spindles characteristics.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture (LP)
Description: Lumbar puncture (LP) to measure CSF P-Tau, T-Tau and Aβ42/40 ratio.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-[11C]Omethylreboxetine ([11C]MRB)
Description: PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-\[11C\]O-methylreboxetine (\[11C\]MRB) to measure NET availability.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychomotor Vigilance Task (PVT)
Description: Psychomotor vigilance task (PVT) and the OddBall to measure test taskattention performance.
Study: NCT03122470

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TRUS biopsy
Description: The TRUS biopsy will be performed per current standard of care. Biopsy cores will be sent to pathology in separately labeled specimen cups. The final pathological results will be compared with pre-biopsy MRI findings.
Study: NCT03004053

Intervention type: DEVICE
Intervention: Reflectance Confocal Microscopy (RCM) endoscope device
Study: NCT04186104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine diagnostic process
Description: Patients follow the procedures of registration, waiting, attendance, waiting, examination, waiting, attendance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial intelligence assisted diagnosis process
Description: Patients follow the procedures of registration, AI recommended examination items, Self-service medical history collection ,examination, waiting, AI-assisted attendance.
Study: NCT03799913

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-MESO CAR-T cells
Description: Retroviral vector-transduced autologous T cells to express anti-MESO CARs
Study: NCT02348008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: Arm A: Phase 1b Cohort 1: 200mg IV; Arm A: Phase 1b Cohort 2: 200mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Arm A: Phase 1b Cohort 1: 10mg IV; Arm A: Phase 1b Cohort 2: 15mg IV
Study: NCT03799913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m2/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300mg/m2/d
Study: NCT06336187

Intervention type: OTHER
Intervention: active surveillance
Description: Follow-up visits will be scheduled 3 (optional) and 6 months after diagnosis, every 6 months up to 3 years and yearly thereafter.
Study: NCT02348008

Intervention type: DRUG
Group type: OTHER
Intervention: MK-3475
Description: Arm B: Phase II Treatment: 200mg IV

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: Arm B: Phase II Treatment: administered at the maximum safe dose of 10mg or 15mg as established in the Phase 1b dose escalation cohort study.
Study: NCT03260790

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV13
Description: Single 0.5 ml dose of PCV13 administered via intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PPSV23
Description: Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23
Description: Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously
Study: NCT02164318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handgrip training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handgrip training

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment
Study: NCT04321083

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: INVOS
Description: INVOS monitoring brain o2 saturation
Study: NCT02253381

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right
Description: Right lateral decubitus position during spinal anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left
Description: Left lateral decubitus position during spinal anesthesia
Study: NCT02335346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Administered orally